How to buy Celgene Corporation stock

Celgene Corporation is a drug manufacturers-general business based in the US. Celgene Corporation shares (CELG) are listed on the NASDAQ and all prices are listed in US Dollars. Celgene Corporation employs 8,852 staff and has a trailing 12-month revenue of around $17 billion.

Celgene Corporation stock price (NASDAQ: CELG)

Use our graph to track the performance of CELG stocks over time.

Celgene Corporation shares at a glance

• Key figures

Information last updated 2020-04-13.

52-week range	$0.00 - $0.00
50-day moving average more info button	$108.24
200-day moving average more info button	$104.36
Wall St. target price	$103.40
PE ratio more info button	13.33
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$8.13

Buy Celgene Corporation stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Celgene Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Celgene Corporation stock undervalued or overvalued?

Valuing Celgene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Celgene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Celgene Corporation's P/E ratio

Celgene Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Celgene Corporation shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Celgene Corporation's PEG ratio

Celgene Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.86. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Celgene Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Celgene Corporation's EBITDA

Celgene Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.9 billion.

The EBITDA is a measure of a Celgene Corporation's overall financial performance and is widely used to measure a its profitability.

Celgene Corporation financials

Revenue TTM	$17 billion
Operating margin TTM	48.75%
Gross profit TTM	$14.1 billion
Return on assets TTM	13.69%
Return on equity TTM	69.39%
Profit margin	34.63%
Book value	$16.99
Market capitalisation more info button	$77 billion

TTM: trailing 12 months

Celgene Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Celgene Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Celgene Corporation's total ESG risk score

Total ESG risk: 23.71

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Celgene Corporation's overall score of 23.71 (as at 12/31/2018) is excellent – landing it in it in the 3rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Celgene Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Celgene Corporation's environmental score

Environmental score: 1.02/100

Celgene Corporation's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Celgene Corporation's social score

Social score: 14.4/100

Celgene Corporation's social score of 14.4 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Celgene Corporation's governance score

Governance score: 5.29/100

Celgene Corporation's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Celgene Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Celgene Corporation's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Celgene Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Celgene Corporation has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Celgene Corporation was last rated for ESG on: 2019-01-01.

Total ESG score	23.71
Total ESG percentile	2.75
Environmental score	1.02
Environmental score percentile	2
Social score	14.4
Social score percentile	2
Governance score	5.29
Governance score percentile	2
Level of controversy	2

Celgene Corporation share dividends

We're not expecting Celgene Corporation to pay a dividend over the next 12 months.

Have Celgene Corporation's shares ever split?

Celgene Corporation's shares were split on a 2:1 basis on 25 June 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Celgene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Celgene Corporation shares which in turn could have impacted Celgene Corporation's share price.

Celgene Corporation share price volatility

Over the last 12 months, Celgene Corporation's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celgene Corporation's is 1.4131. This would suggest that Celgene Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Celgene Corporation overview

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc. ; Agios Pharmaceuticals, Inc. ; bluebird bio, Inc.

Frequently asked questions

What percentage of Celgene Corporation is owned by institutions?
Currently 78% of Celgene Corporation shares are held by institutions. How many people work for Celgene Corporation?
Latest data suggests 8,852 work at Celgene Corporation. When does the fiscal year end for Celgene Corporation?
Celgene Corporation's fiscal year ends in December. Where is Celgene Corporation based?
Celgene Corporation's address is: 86 Morris Avenue, Summit, NJ, United States, 07901 What is Celgene Corporation's ISIN number?
Celgene Corporation's international securities identification number is: US1510201049 What is Celgene Corporation's CUSIP number?
Celgene Corporation's Committee on Uniform Securities Identification Procedures number is: 151020104